ArticleMolecular cytogenetics2018
Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse.
Article in Molecular cytogenetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Extramedullary metastasis of the hilar bile duct in multiple myeloma: a case report and literature review.Journal of gastrointestinal oncology · 2025Article
- Extramedullary Multiple Myeloma: Challenges and Opportunities.Current oncology (Toronto, Ont.) · 2025Review
- ISCN and Chromoanagenesis.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Chromothripsis is a novel biomarker for prognosis and differentiation diagnosis of pancreatic neuroendocrine neoplasms.MedComm · 2024Article
- Genetic Abnormalities in Extramedullary Multiple Myeloma.International journal of molecular sciences · 2023Review
- [Multiple myeloma with chromothripsis: three cases report].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Insight into the Molecular Basis Underlying Chromothripsis.International journal of molecular sciences · 2022Review
- Review
- Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma.Cancers · 2021Review
- Somatic Genomic Mosaicism in Multiple Myeloma.Frontiers in genetics · 2020Article
- Germline Risk Contribution to Genomic Instability in Multiple Myeloma.Frontiers in genetics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCatastrophic chromosomal event known as chromothripsis was proven to be a significant hallmark of poor prognosis in several cancer diseases. While this phenomenon is very rare in among multiple myeloma (MM) patients, its presence in karyotype is associated with very poor prognosis. CASE PRESENTATION: In our case, we report a 62 year female patient with rapid progression of multiple myeloma (MM) into extramedullary disease and short overall survival (OS = 23 months). I-FISH investigation revealed presence of gain 1q21 and hyperdiploidy (+ 5,+ 9,+ 15) in 82% and 86%, respectively, while
conclusionsOur findings suggest that presence of chromothripsis should be considered as another important genetic hallmark of poor prognosis in MM patients and utilization of genome-wide screening techniques such as array-CGH and NGS improves the clinical diagnostics of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.